<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Local cerebral blood flow (CBF) in the steady state and after intravenous administration of <z:chebi fb="0" ids="15765">levodopa</z:chebi> (1 mg/kg) was measured by <z:chebi fb="3" ids="49957">xenon</z:chebi>-enhanced computed tomography in patients with <z:e sem="disease" ids="C0030567" disease_type="Disease or Syndrome" abbrv="PD">Parkinson's disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>, n = 16), <z:e sem="disease" ids="C0038868" disease_type="Disease or Syndrome" abbrv="PSNP1">progressive supranuclear palsy</z:e> (PSP, n = 6), <z:hpo ids='HP_0002542'>olivopontocerebellar atrophy</z:hpo> (OPCA, n = 5), and arteriosclerotic <z:hpo ids='HP_0001300'>parkinsonism</z:hpo> (AP, n = 7) </plain></SENT>
<SENT sid="1" pm="."><plain>Three patterns of local CBF changes following <z:chebi fb="0" ids="15765">levodopa</z:chebi> were observed: (1) diffuse CBF increases, especially in striatum and thalamus, as found in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>; (2) no significant changes in CBF, as in patients with OPCA and AP; and (3) CBF reductions in basal ganglia and thalamus, as seen in patients with PSP </plain></SENT>
<SENT sid="2" pm="."><plain>The CBF increases after <z:chebi fb="0" ids="15765">levodopa</z:chebi> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e> may be secondary to metabolic activation of the nigrostriatal dopaminergic system </plain></SENT>
<SENT sid="3" pm="."><plain>The poor CBF responses in patients with OPCA, AP, and PSP appeared to reflect degeneration of the dopaminergic neurons and <z:chebi fb="40" ids="18243">dopamine</z:chebi> receptors to various degrees </plain></SENT>
<SENT sid="4" pm="."><plain>The CBF increases, especially in striatum and thalamus, tended to be greater (not significant) among responders to oral <z:chebi fb="0" ids="15765">levodopa</z:chebi> therapy </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="15765">Levodopa</z:chebi>-induced CBF measurements may be useful for the differential diagnosis of <z:e sem="disease" ids="C0242422" disease_type="Disease or Syndrome" abbrv="">parkinsonian syndromes</z:e> of various etiologies, but are not necessarily sufficient for predicting outcomes of long-term <z:chebi fb="0" ids="15765">levodopa</z:chebi> therapy </plain></SENT>
</text></document>